Meeting the Need: Navigating and Implementing Long-Acting Injectables and Other Provider-Administered Drugs

Tim Horn

Director, Medication Access



Learning Objectives

By the end of this session, participants will be able to:

- 1. Understand the scientific evidence supporting the availability of longacting injectable and other provider-administered ARVs, including their potential needs among people with HIV.
- 2. Identify systems-level implementation considerations, including potential coordination needs with state/territorial ADAP.
- 3. Navigate procurement and payment factors associated with securing access for full-pay medication program ADAP clients.
- 4. Assess public and private payer coverage and cost-sharing assistance mechanisms for insured ADAP clients.



Presentation Roadmap

- 1. Long-Acting and Provider-Administered Medication Background
- 2. Long-Acting and Provider Administered Medication Profiles
- 3. Procurement Considerations
- 4. ADAP Full-Pay Medication Program Coverage
- 5. ADAP-Funded Insurance Program Coverage
- 6. Questions and Discussion (Including State/Territory Experiences)

What is a Long-Acting Medication?


Drug or biologic formulation engineered to achieve the following over an extended period of time:

- Maintain therapeutic and efficacious levels
- Be slowly absorbed relative to the dose
- Persist in the tissues before being metabolized or excreted
- May be injectable, infusible, implantable, or oral

Longer half-life compared to immediate, or delayed release formulations.



Immediate Release vs. Long-Acting (LA) Medication





What is a Provider-Administered (PA) Drug?

Drug or biologic formulation that is typically administered by a health care provider in a physician's office, clinic, or other outpatient setting.

- May include infused, injected, or implanted medications
- May be required to ensure correct administration, due to supply-chain requirements (e.g., cold storage), or cost
- Includes products for long-acting treatment as well as medicines for specific conditions
- Non-clinic sites of administration may include infusion centers, pharmacies, home infusion



Potential Advantages of LA and PA Antiretrovirals

- Less frequent dosing
- Avoidance of "pill fatigue"
- Improved adherence
- Oral dosing bypassed
- Fewer and/or less severe side effects/toxicity
- Fewer drug-drug interactions
- Protection of health privacy
- Avoidance of HIV-related stigma
- Novel mechanism for delivering drugs and biologics that can't be administered orally



LA and PA Antiretroviral Drug and Biological Products







Cabotegravir/Rilpivirine Approved: January 2021 Ibalizumab-uiyk Approved: March 2018 Lenacapavir Approved: December 2022



LA and PA Medicine Profiles




Cabotegravir & Rilpivirine

Attributes	Description	
ARV Class	Cabotegravir: integrase strand transfer inhibitor Rilpivirine: non-nucleoside reverse transcriptase inhibitor	
Key Clinical Trials	ATLAS, FLAIR, ATLAS-2M	
Indication	For patients who are virally suppressed on a stable oral ARV regimen, with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine	
Administration	Intramuscular injection (gluteal); optional oral lead-in	
Dosing	Oral lead-in: 30 mg CAB + 25 mg RPV daily for four weeks Initiation/Loading: Two 3 mL IM injections Maintenance: two 2 mL IM injections every month or two 3 mL IM injections every two months	
Additional Info	Cold-chain storage	



Cabotegravir & Rilpivirine – Looking Ahead

- UCSF Ward 86 in SF serves publicly insured and underinsured patients; high levels of marginal housing and stimulant use.
- Study of monthly CAB/RPV in 51 patients; 15 with detectable HIV-RNA, adherence challenges.
- 12/15 achieved viral suppression; 3 others had significant drops in viral load.
- Potential for initiating antiretroviral treatment with LA CAB/RPB in hard-toreach populations with adherence challenges.



Christopoulos, et al. Clin Infect Dis. 2023 Feb 8;76(3):e645-e651



Ibalizumab

Attributes	Description	
ARV Class	CD4 post-attachment inhibitor (monoclonal antibody)	
Key Clinical Trials	TMB-301, TMB-302	
Indication	For heavily treatment-experienced patients with multidrug-resistance HIV failing their current antiretroviral regimen	
Administration	Intravenous infusions; no oral lead-in required	
Dosing	Initiation/Loading: 2,000 mg IV infusion (10 2 mL vials) Maintenance: 800 mg IV infusion (4 2 mL vials) every two weeks (30 second "Push" infusion or 15 minute infusion)	
Additional Info	Cold-chain storage	



Lenacapavir

Attributes	Description	
ARV Class	Capsid inhibitor	
Key Clinical Trials	CAPELLA	
Indication	For heavily treatment-experienced patients with multidrug-resistance HIV failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations	
Administration	Subcutaneous injections (abdomen); oral dosing required during initiation	
Dosing	Initiation/Loading: 927 mg SC injection (2 1.5 mL injections) plus 600 mg (2 300 mg tablets) orally on Day 1 and 600 mg orally on Day 2 <u>or</u> 600 mg orally on day 1, 2, and 8 plus 927 mg SC injection on Day 15 Maintenance: 927 mg SC injection (2 1.5 mg injections) every six months	
Additional Info	Room temperature storage	



Lenacapavir – Looking Ahead

- Lenacapavir/bictegravir oral combination virologically suppressed treatmentexperienced people
- Lenacapavir/islatravir oral combination long-acting HIV treatment for virologically suppressed people
- No clear partner (drug) for long-acting treatment regimen
- Early studies of combinations with monoclonal antibodies and other long-acting products in development
- Anecdotal use of lenacapavir plus stand-alone injectable cabotegravir for heavily-treatment experienced patients



Procurement Considerations




Limited Distribution Models

- Provider-administered drugs typically available under limited distribution models
- Key players:
 - **Specialty distributors** typically sell specialty drugs and biologics directly to physicians' offices, clinics, and hospitals; purchasers (including direct-purchase ADAPs) may be able to leverage relationship with wholesalers with specialty distributor divisions or subsidiaries. Frequent source of drugs/biologics for buy-and-bill.
 - **Specialty pharmacies** typically dispense drugs directly to patients or, where provider administration is required, directly to patients' health care provider. Frequent source of drugs/biologics via white bagging.




Buy-and-Bill



Long-Acting Injectable (LAI) Antiretroviral Therapy (ART): Coverage and Cost-Sharing Considerations for Ryan White HIV/AIDS Program (RWHAP) Clients. ACE TA Center/JSI. 2022.

White Bagging



Long-Acting Injectable (LAI) Antiretroviral Therapy (ART): Coverage and Cost-Sharing Considerations for Ryan White HIV/AIDS Program (RWHAP) Clients. ACE TA Center/JSI. 2022.

18

Specialty Distributors and Specialty Pharmacies

	Specialty Distributors	Specialty Pharmacies
Cabotegravir/ Rilpivirine	ASD Specialty Distribution, Besse Medical, Cardinal Health Specialty, Curascript Specialty Distribution, McKesson Plasma and Biologics, McKesson Specialty Health, McKesson MedicalSurgical, and Oncology Supply	Accredo Health Group, Inc, AHF Pharmacy, Coordinated Care Network, Curant Health, CVS Specialty, Diplomat (Optum), Fairview Specialty, Humana Specialty Pharmacy, Kroger Specialty Pharmacy, Longs/Avita Specialty, Mail-Meds Clinical Pharmacy, Meijer Specialty, Optum/Avella, Walgreens/AllianceRx Prime
Ibalizumab	CuraScript SD	Accredo Health Group, Inc, Walgreens/AllianceRx Prime
Lenacapavir	ASD Specialty Distribution, Cardinal Health Specialty	CVS Specialty





ADAP Full-Pay Medication Program Coverage

Direct Purchase Mechanism

- Leverage ship-to/bill-to replenishment with a 340B contract pharmacy within product's specialty pharmacy network.
- Leverage specialty distributor (and, potentially, associated mainline wholesaler) contract to purchase for central pharmacy dispenses directly to providers (white-bagging).
- Where allowable, leverage specialty distributor (or associated mainline wholesaler) contract to purchase for contract pharmacy dispenses directly to providers.

Establishing sole source contract and other strategies to contend with limited distribution models will depend on state/territory procurement requirements



Rebate Mechanism – White-Bagging Model

- LA or PA drug/biologic is dispensed by ADAP network pharmacy that is part of manufacturer's specialty pharmacy network.
- Specialty pharmacy ships product to provider for administration to ADAP clients and invoices ADAP (or PBM on its behalf) at contracted reimbursement rate.
- ADAP (or PBM) reimburses specialty pharmacy and then files a rebate claim with manufacturer.

Establishing sole source contract and other strategies to contend with limited distribution models will depend on state/territory procurement requirements



Rebate Mechanism – Buy-and-Bill Model

- ADAP establishes a network of providers (e.g., RWHAP Part B subrecipients) that may draw on their own inventory of LA and PA drugs/biologics.
- Provider submits invoices to ADAP or vendor (e.g., medical benefit manager) at contract reimbursement rate.
- ADAP reimburses the provider and then files a rebate with manufacturer.

Reminder: As a primary payer for eligible people with HIV, ADAPs may choose how to procure and/or cover LA and PA medications for their full-pay programs



Medication Administration Costs

Dear Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program Colleagues: The U.S. Food and Drug Administration (FDA) is expected to soon approve a long-acting antiretroviral (ARV) medication. Long-acting ARV medications have the potential to address challenges related to treatment adherence. However, long-acting ARVs will likely involve **administration and** result. The Health etermined the cost of ury, including the cost ie cost under the ADAP clients with health care

> ng-acting ARVs ration of challenges ADAPs play a key g the goals of the edications are ng ARVs to their

Health Resources and Services

Administration Rockville, MD 20857

HIV/AIDS Bureau

medications may require increased medical office visits for medication administration and RWHAP providers may experience increased costs for office visits as a result. The Health Resources and Services Administration's (HRSA) HIV/AIDS Bureau determined the cost of administering an antiretroviral medication on the RWHAP ADAP formulary, including the cost of an office visit exclusively for medication administration, is an allowable cost under the ADAP service category (see § 2616(c)(4) of the Public Health Service Act). For clients with health care

Please contact your RWHAP Part B project officer in the Division of State HIV/AIDS Programs if you have any questions and to share any challenges you are facing, or anticipate facing, concerning this issue.

DEPARTMENT OF HEALTH & HUMAN SERVICES

DEC - 4 2019

Sincerely,

/Laura W. Cheever/


Laura W. Cheever, MD, ScM Associate Administrator

Long-Acting Anitretroviral (ARV) Medication Guidance and Ryan White HIV/AIDS Program. HRSA HAB. 2019.



Medication Administration Costs

- Where white bagging is used, a separate claim from a provider may include allowable administration or office visit costs (submitted to ADAP or vendor).
- Where a buy-and-bill mechanism is used, provider claim may include the allowable cost of the medication plus administration or office visit costs.
- Where ADAPs choose to cover these costs, payment rates may be negotiated with provider.
- Where ADAP chooses not to cover these costs, RWHAP Outpatient/Ambulatory Health Services (OAHS) service category may also be used.



25

ADAP-Funded Insurance Program Coverage



26

Pharmacy Benefit or Medical Benefit?


- **Pharmacy benefit:** Pharmacy benefits are listed on a plan's formulary, available on the plan's Summary of Benefits and Coverage. Clients should check this formulary first.
- **Medical benefit:** Often plans will have a separate list from their standard formulary called "specialty medical benefit drugs" or "medical benefit injectable drugs" where LA and PA products may be found.
- Medicare mostly covers LA and PA antiretrovirals under Part B medical benefit; they may be covered under Part D or Medicare Advantage pharmacy benefit.



Insurance Cost Sharing Requirements

- LA and PA medications covered as a medical benefit by **commercial insurance plans** often require a flat co-insurance rate (e.g., 20% of the total cost of the medication), typically after the plan deductible requirement has been met.
- For **Medicare** clients, LA and PA medications are often covered under Part B as a provider-administered drug; 20% cost sharing may apply.
 - Supplemental insurance coverage, Medicaid dual eligibility, or enrollment in the Qualified Medicare Beneficiary (QMB) program may defray cost-sharing requirements.
 - Some Medicare Advantage plans that include prescription drug coverage (Part D) may opt to cover LA and PA medications as a pharmacy benefit; potential lower cost sharing and out of pocket (OOP) cap.
- **Medicaid** cost-sharing is typically nominal.





Long-Acting Antretroviral (ARV) Medication Guidance and Ryan White HIV/AIDS Program. HRSA HAB. 2019.



ADAP Cost-Sharing Coverage Considerations

- LA and PA medication coverage as pharmacy benefit provides greater opportunity for ADAPs to make cost-sharing payments (and collect partial-pay rebates), when the specialty pharmacy that dispenses the medication is in the ADAP's pharmacy network.
- Utilizing manufacturer copay assistance programs possible where ADAP cannot provide cost-sharing assistance.
 - copays.org potential source of assistance for Medicare cost sharing.
- Potential growth of LA and PA medication needs by people with HIV presents opportunity for ADAPs to explore provider-based coverage mechanisms.
- When ADAP chooses not to cover these costs, RWHAP Premium and Cost-Sharing Assistance for Low-Income Individuals service category may be used.



Questions and Discussion State/Territorial ADAP Experiences



31

Thank you! thorn@NASTAD.org



32